ZIOPHARM Oncology Inc (ZIOP) : During the past 4 weeks, traders have been relatively bearish on ZIOPHARM Oncology Inc (ZIOP), hence the stock is down -25.43% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -10.93% relative to the S&P 500. The 4-week change in the price of the stock is -20.39% and the stock has fallen -10.38% in the past 1 week.
ZIOPHARM Oncology Inc (NASDAQ:ZIOP): The stock opened at $4.60 on Friday but the bulls could not build on the opening and the stock topped out at $4.64 for the day. The stock traded down to $4.46 during the day, due to lack of any buying support eventually closed down at $4.49 with a loss of -2.39% for the day. The stock had closed at $4.60 on the previous day. The total traded volume was 2,117,867 shares.
The stock has recorded a 20-day Moving Average of 18.92% and the 50-Day Moving Average is 29.27%. ZIOPHARM Oncology, Inc. has dropped 44.5% during the last 3-month period . Year-to-Date the stock performance stands at -45.97%.
ZIOPHARM Oncology, Inc. is a biopharmaceutical company. The Company is engaged in the acquisition, development and commercialization of a portfolio of cancer therapies through synthetic biology. The Companys pipeline includes a number of cell-based therapeutics in both clinical and preclinical testing which are focused on hematologic and solid tumor malignancies. The Companys clinical stage product candidate, Ad-RTS-IL-12 is used with the oral activator veledimex being developed for the treatment of oncology. Ad-RTS-IL-12 in combination with veledimex uses the synthetic biology platform (gene-delivery system) to produce Interleukin-12, or IL-12, a potent, naturally occurring anti-cancer protein. The Company has completed two Phase II studies evaluating Ad-RTS-IL-12 in combination with veledimex, for the treatment of metastatic melanoma, and for the treatment of metastatic breast cancer. The Company is also developing CAR-T Cells (Cytokine products).